Anticoagulation for Valvular Heart Disease

May 18, 2015   |  Anthony Carnicelli, MD, FACC

Expert Analysis

Introduction Valvular heart disease (VHD) is a common contributor to cardiac morbidity and mortality.1-3 Current data estimate the overall prevalence of VHD in the United States to be 2.5%, with prevalence estimates in those over the age of 75 to...

Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Cardiac Surgery, Cardiovascular Care Team, Dyslipidemia, Geriatric Cardiology, Heart Failure and Cardiomyopathies, Valvular Heart Disease, Anticoagulation Management and Atrial Fibrillation, Atrial Fibrillation/Supraventricular Arrhythmias, Aortic Surgery, Cardiac Surgery and Arrhythmias, Cardiac Surgery and Heart Failure, Cardiac Surgery and VHD, Lipid Metabolism, Novel Agents

Keywords: Aged, American Heart Association, Anticoagulants, Aortic Valve, Aspirin, Atrial Fibrillation, Benzimidazoles, Cohort Studies, Confidence Intervals, Consensus, Creatinine, Embolism, Factor Xa, Fibrinolytic Agents, Heart Valve Diseases, Heart Valve Prosthesis, International Normalized Ratio, Longitudinal Studies, Mitral Valve, Myocardial Infarction, Numbers Needed To Treat, Odds Ratio, Patient Compliance, Patient Readmission, Platelet Aggregation Inhibitors, Prevalence, Pyrazoles, Pyridines, Pyridones, Surveys and Questionnaires, Registries, Research Personnel, Retrospective Studies, Risk Factors, Risk Reduction Behavior, Stroke, Sutures, Thiazoles, Thromboembolism, Thrombosis, Ticlopidine, Uncertainty, Ventricular Dysfunction, Left, Vitamin K, Warfarin, beta-Alanine